-
公开(公告)号：US20170334896A1
公开(公告)日：2017-11-23
申请号：US15522985
申请日：2015-10-29
Applicant: Xiamen University
Inventor： Zuguo LIU , Yan QIU , Jie REN , Yuhang LI , Longhe YANG , Chenggang ZHU
IPC: C07D413/14 , C07D263/26 , C07D207/28 , C07D413/06 , C07D207/273
CPC classification number: C07D413/14 , C07D207/273 , C07D207/28 , C07D263/26 , C07D413/06
Abstract: The invention provides a compound as shown by Formula I having an enzyme activity which can inhibit endocannabinoid hydrolases NAAA and/or FAAH, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a preparation method and a use of the compound.
-
公开(公告)号：US09764028B2
公开(公告)日：2017-09-19
申请号：US15248850
申请日：2016-08-26
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Shaowei Li , Cuiling Song , Chunyan Yang , Ying Gu , Wenxin Luo , Ningshao Xia
IPC: C07K14/34 , C07K14/005 , A61K39/29 , C12N15/62 , A61K39/39 , C12N9/10 , A61K39/12 , A61K39/05 , C12N7/00 , A61K38/00 , A61K39/00
CPC classification number: A61K39/39 , A61K38/00 , A61K39/05 , A61K39/12 , A61K39/29 , A61K2039/55505 , A61K2039/55516 , A61K2039/55544 , A61K2039/6037 , C07K14/005 , C07K14/34 , C07K2319/03 , C07K2319/55 , C07K2319/74 , C12N7/00 , C12N9/1048 , C12N15/62 , C12N2760/16122 , C12N2760/16134 , C12N2770/28122 , C12N2770/28134
Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
-
公开(公告)号：US09739700B2
公开(公告)日：2017-08-22
申请号：US14434914
申请日：2013-09-03
Applicant: XIAMEN UNIVERSITY
Inventor： Xiaomei Yan , Shaobin Zhu
CPC classification number: G01N15/1434 , G01N15/1459 , G01N21/53 , G01N21/85 , G01N2015/0038 , G01N2015/1413 , G01N2015/1447 , G01N2201/06113
Abstract: Disclosed is a method for detecting nano-particles, comprising the steps of (1) compressing a sample liquid to be tested into a sample liquid flow by hydrodynamic focusing using a sheath fluid; (2) irradiating a measuring light to the sample liquid flow, wherein a single nano-particle in the sample liquid flow is irradiated by the measuring light for a duration of 0.1-10 milliseconds; (3) defining the area in which the measuring light irradiates the sample liquid flow as a detecting area, and collecting light signals emitted from the area irradiated by the measuring light by a lens imaging system, and allowing the light signals collected by the lens imaging system to pass a field stop, so as to filter out the light signals outside the detecting area and enrich the light signals from the detecting area; and (4) subjecting the light signals enriched by the field stop to optoelectronic signal conversion. The method can achieve detection for nano-particles with a low refractive index and a particle size of 24-1000 nm as well as nano-scale gold particles with a particle size of 6.7-150 nm.
-
64.发明授权公开(公告)号：US09650434B2
公开(公告)日：2017-05-16
申请号：US14781391
申请日：2014-04-02
Applicant: Xiamen University
Inventor： Yixin Chen , Qingbing Zheng , Rui Li , Chenguang Shen , Shaojun Ke , Wenxin Luo , Honglin Chen , Ningshao Xia
IPC: C07K16/10 , G01N33/569 , A61K39/00
CPC classification number: C07K16/1018 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/76 , G01N33/56983 , G01N2333/11 , G01N2469/10
Abstract: The invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin (HA) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also relates to vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g. influenza), comprising the antibodies according to the invention.
-
公开(公告)号：US20170073488A1
公开(公告)日：2017-03-16
申请号：US15125378
申请日：2014-12-04
Applicant: XIAMEN UNIVERSITY
Inventor： Lizong DAI , Cong XIE , Wei'ang LUO , Birong ZENG , Yiting XU , Xinyu LIU , Kaibin HE , Qi LI , Yuanyuan LI , Xianming CHEN
CPC classification number: C08J9/0038 , C08G18/165 , C08G18/18 , C08G18/1825 , C08G18/2063 , C08G18/242 , C08G18/246 , C08G18/3878 , C08G18/4883 , C08G18/6696 , C08G2101/0025 , C08G2101/0083 , C08J9/0014 , C08J9/0023 , C08J9/0028 , C08J9/0052 , C08J9/0061 , C08J9/0095 , C08J9/125 , C08J2201/022 , C08J2203/10 , C08J2205/10 , C08J2375/08 , C08J2483/00 , C08J2483/12
Abstract: The present invention provides a kind of inherent flame retardant rigid polyurethane foam. The production formula comprises 100 to 105 pbw of polyether polyol and reactive phosphorus-containing flame retardant, 2.5 to 3.5 pbw of amine catalyst, 0.8 to 2.5 pbw of tertiary amine catalyst, 0.8 to 2.5 pbw of foam stabilizer, 0.5 to 1.5 pbw of blowing agent, 135 to 150 pbw of isocyanates, and 0.05 to 0.1 pbw of organo-metallic catalyst, wherein the reactive phosphorus-containing flame retardant is 9,10-dihydro-9-oxa-10-phosphaphenanthrene-4-hydroxybenzyl alcohol. The active monomers containing flame retarding elements are introduced into main chain and side chain of PU for modification, which permanently improves the flame retardancy of PU without obvious effect on other performance of PU matrix.
Abstract translation: 本发明提供了一种固有的阻燃硬质聚氨酯泡沫塑料。 该制造方法包括100至105pbw的聚醚多元醇和反应性含磷阻燃剂，2.5至3.5pbw的胺催化剂，0.8至2.5pbw的叔胺催化剂，0.8至2.5pbw的泡沫稳定剂，0.5至1.5pbw的吹塑 试剂，135〜150pbw的异氰酸酯和0.05〜0.1pbw的有机金属催化剂，其中，反应性含磷阻燃剂为9,10-二氢-9-氧杂-10-磷杂菲-4-羟基苄醇。 将含有阻燃元素的活性单体引入PU的主链和侧链进行改性，永久改善PU的阻燃性，对PU基体的其他性能没有明显的影响。
-
Patent Agency Ranking
公开(公告)号：US20170065708A1
公开(公告)日：2017-03-09
申请号：US15350264
申请日：2016-11-14
Inventor： Jun Zhang , Jin Wang , Chunyan Yang , Ying Gu , Shaowei Li , Ningshao Xia
IPC: A61K39/12 , C07K14/005 , C12N7/00
CPC classification number: A61K39/12 , C07K14/005 , C12N7/00 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034
Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
Abstract translation: 本发明涉及11型人乳头瘤病毒的截短的L1蛋白，由蛋白组成的病毒样颗粒，包含所述病毒样颗粒的疫苗，以及该疫苗在预防尖锐湿疣或HPV感染中的用途。
-
67.发明申请Broad-Spectrum Monoclonal Antibody Recognizing HA1 Domain of Hemagglutinin of Influenza Virus 有权广谱单克隆抗体识别流感病毒血凝素的HA1结构域公开(公告)号：US20160145320A1
公开(公告)日：2016-05-26
申请号：US14781391
申请日：2014-04-02
Applicant: XIAMEN UNIVERSITY
Inventor： Yixin CHEN , Qingbing ZHENG , Rui LI , Chenguang SHEN , Shaojun KE , Wenxin LUO , Honglin CHEN , Ningshao XIA
IPC: C07K16/10 , G01N33/569
CPC classification number: C07K16/1018 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/76 , G01N33/56983 , G01N2333/11 , G01N2469/10
Abstract: The invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin (HA) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also relates to vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g. influenza), comprising the antibodies according to the invention.
Abstract translation: 本发明涉及识别流感病毒血凝素（HA）蛋白HA1结构域上的抗原表位的抗体，用于产生抗体的细胞系及其用途。 根据本发明的抗体可以特异性结合不同HA亚型的HA1结构域，并特异性结合H1亚型（包括季节性H1N1和2009大流行H1N1）和流感病毒H5亚型的血凝素（HA）蛋白的HA1结构域。 因此，本发明还涉及用于预防和/或治疗H1亚型和H5亚型流感病毒感染的疫苗或药物组合物和/或由包含本发明的抗体的感染（例如流感）引起的疾病。
-
公开(公告)号：US09334533B2
公开(公告)日：2016-05-10
申请号：US14182067
申请日：2014-02-17
Applicant: XIAMEN UNIVERSITY
Inventor： Qingge Li , Qiuying Huang
CPC classification number: C12Q1/6858 , C12Q1/6827 , C12Q2527/107 , C12Q2531/107 , C12Q2535/131
Abstract: The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described.
Abstract translation: 本发明涉及使用熔解曲线分析检测核酸序列变异的方法和试剂盒，特别涉及通过使用自淬灭探针的熔解曲线分析来检测核酸序列变异的方法和试剂盒。 所述方法提供了使用的自淬灭探针的特征，以及相应的核酸扩增条件，使得探针可以结合扩增的靶序列，并且可以通过熔解曲线分析来检测靶序列的变化。 本发明还包括根据所述方法组装的试剂盒。
-
69.发明申请ANTI-HBC QUANTITATIVE DETECTION METHOD AND USES THEREOF IN MONITORING AND CONTROLLING DISEASE PROGRESSION OF CHRONIC HEPATITIS B PATIENT AND IN PREDICTING THERAPEUTIC EFFECT 有权抗HBC定量检测方法及其在监测和控制慢性乙型肝炎患者疾病进展和预防治疗效果方面的应用公开(公告)号：US20150118674A1
公开(公告)日：2015-04-30
申请号：US14373611
申请日：2013-01-17
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Quan Yuan , Liuwei Song , Wenbin Zhou , Zuxing Weng , Feihai Xu , Shengxiang Ge , Jun Zhang , Ningshao Xia
IPC: G01N33/569
CPC classification number: G01N33/56983 , G01N33/5762 , G01N2333/02 , G01N2469/20 , G01N2800/52 , G01N2800/56
Abstract: The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analogue anti-HBV drug), and thus guide the patients to reasonably choose drugs.
Abstract translation: 本发明涉及一种用于定量检测抗HBc的方法及其在监测慢性乙型肝炎患者疾病进展和预测治疗效果中的应用。 通过定量检测抗乙型肝炎核心蛋白（Anti-HBc）的抗体，能够监测慢性乙型肝炎患者的疾病进展，有效预测接受乙型肝炎病毒治疗的慢性乙型肝炎患者的治疗效果（特别是 基于干扰素的治疗和基于核苷/核苷酸类似物抗HBV药物的治疗），从而指导患者合理选择药物。
-
公开(公告)号：US20250057999A1
公开(公告)日：2025-02-20
申请号：US18893474
申请日：2024-09-23
Applicant: XIAMEN UNIVERSITY
Inventor： Zhide GUO , Xingxing CHENG , Xianzhong ZHANG , Hongwu LIU , Xueqi WANG
Abstract: Provided is a glutamic acid (Glu)-urea compound and a preparation method and use thereof. The Glu-urea compound and the nuclide-targeted probe have excellent in vivo biological properties and show a high specific uptake in lesions with high expression of a prostate-specific membrane antigen (PSMA) protein. The compound and probe have a high target/non-target ratio, low non-specific background activity, and significantly-enhanced tumor uptake and retention time. The compound and probe are suitable for use in the nuclide therapy and imaging of tumors, and can also reduce unnecessary radiation damage to normal tissues and organs. The compound and probe can also overcome the shortcomings such as low target organ uptake and short retention time of small-molecule PSMA, and improve the effects of PSMA-targeted nuclide therapy and imaging, thus exhibiting a potential to be widely used in clinical applications.
-
-
-
-
-
-
-
-
-
Search Results
316
records
(took 0.018 seconds)
